Similar Articles |
|
The Motley Fool October 20, 2009 Brian Orelli |
Pfizer Starts the Blame Game Pfizer beat analysts' expectations for both revenue and adjusted earnings, but revenue was still lower than the year-ago quarter. Pfizer has excuses. |
The Motley Fool January 17, 2012 Brian Orelli |
You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again. |
The Motley Fool March 3, 2010 Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool October 21, 2008 Brian Orelli |
The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch. |
The Motley Fool January 23, 2009 Brian Orelli |
Wyeth Isn't Cheap Enough for Pfizer The Wall Street Journal reports that Pfizer is in talks to acquire Wyeth for $60 billion or more. Should they do it? |
The Motley Fool October 19, 2009 Brian Orelli |
Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease. |
The Motley Fool April 11, 2011 Brian Orelli |
Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected. |
The Motley Fool September 15, 2009 Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
The Motley Fool May 12, 2009 Brian Orelli |
Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners. |
The Motley Fool September 30, 2009 Brian Orelli |
More Questions Than Answers From Elan Things that make you go hmmm. |
The Motley Fool January 28, 2010 Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. |
The Motley Fool October 30, 2009 Brian Orelli |
World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth. |
The Motley Fool April 27, 2009 Jim Mueller |
Foolish Forecast: Pfizer's Out of the Starting Gate In advance of earnings, analyst's expect revenue down 6%, but none are saying to dump the stock. |
The Motley Fool December 18, 2008 Brian Orelli |
Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009. |
The Motley Fool January 29, 2010 Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool February 22, 2007 Brian Lawler |
Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today. |
The Motley Fool July 31, 2008 Brian Lawler |
Examining Elan's Ups and Downs Was the pharmaceutical's news about its potential Alzheimer's treatment as bad as investors treated it? |
The Motley Fool February 22, 2007 Ryan Fuhrmann |
Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note. |
The Motley Fool October 20, 2008 Brian Orelli |
Foolish Forecast: Will Pfizer Flounder Through Another Quarter? Pharmaceutical giant Pfizer releases earnings tomorrow morning. Let's take a look at what the numbers might say and, more importantly, what management might be able to say to get this stock out of its drug-induced coma. |
The Motley Fool January 26, 2009 Brian Orelli |
Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place. |
The Motley Fool September 5, 2008 Brian Lawler |
Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon. |
The Motley Fool December 29, 2009 Brian Orelli |
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. |
The Motley Fool February 3, 2010 Brian Orelli |
Wyeth Can't Save Pfizer Not much earnings growth, but the price is right. |
The Motley Fool July 21, 2009 Brian Orelli |
Foolish Forecast: Pfizer Meanders Toward Merger Let's look at what to expect when the pharmaceutical giant releases earnings tomorrow. |
The Motley Fool April 28, 2009 Brian Orelli |
The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case. |
The Motley Fool July 18, 2007 Ryan Fuhrmann |
Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note. |
The Motley Fool October 20, 2006 Brian Lawler |
Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth. |
The Motley Fool March 13, 2009 Brian Orelli |
Pfizer Finally Gets a Hit! Positive results on Pfizer's cancer drug Sutent come earlier than expected. |
The Motley Fool May 21, 2009 Brian Orelli |
Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose. |
The Motley Fool June 25, 2009 Brian Orelli |
Pfizer Gets a Double After a couple of disappointing trials for Pfizer's Sutent, investors get some good news about the drug. |
The Motley Fool January 27, 2009 Brian Orelli |
Amgen's Anemic Again 2009 won't be stellar, but the future looks better. |
The Motley Fool July 2, 2009 Brian Orelli |
Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company. |
The Motley Fool February 2, 2011 Brian Orelli |
Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks. |
Chemistry World August 9, 2012 |
Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials. |
The Motley Fool December 7, 2010 Brian Orelli |
How Pfizer's New Chief Can Right the Ship Bigger is not always better. |
The Motley Fool January 15, 2009 Robert Steyer |
For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move? |
The Motley Fool June 15, 2010 Brian Orelli |
Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer. |
The Motley Fool August 12, 2010 Brian Orelli |
Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment. |
The Motley Fool April 4, 2011 Brian Orelli |
Pfizer Tests the Breakup Waters The company announced today that it found a buyer for its Capsugel unit, which will bring in a cool $2.4 billion. |
The Motley Fool March 10, 2009 Brian Orelli |
So Much Potential, So Little Growth In its quest to become the Johnson & Johnson of China, this purveyor of traditional Chinese medicine has been growing through acquisitions, but has paid for them through dilutive stock offerings. |
The Motley Fool September 3, 2010 Brian Orelli |
Why You Just Got Hammered Celldex's decline is due to potential reasons Pfizer would send back a drug it's been working on with Celldex for over two years |
The Motley Fool October 22, 2009 Brian Orelli |
Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated. |
The Motley Fool April 20, 2007 Ryan Fuhrmann |
Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors. |
The Motley Fool June 8, 2011 Brian Orelli |
Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming. |
The Motley Fool January 19, 2007 Ryan Fuhrmann |
The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price. |
The Motley Fool April 21, 2008 Brian Lawler |
Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits. |
The Motley Fool December 14, 2005 Steven Mallas |
Pfizer: Of Drugs and Dividends Pfizer is raising its payout. Is it a good move for the drugmaker? Investors willing to hold for years while reinvesting dividends will most likely be rewarded along the way. |
The Motley Fool February 10, 2006 Brian Gorman |
Pfizer in Pflux The company is working on its transition, but things still look fairly murky for investors. |
The Motley Fool February 29, 2008 Brian Orelli |
2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed. |
The Motley Fool February 22, 2007 Ryan Fuhrmann |
Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008. |